These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21610317)

  • 1. Brca2 deficiency and Trp53 deregulation in pancreatic cancer: implications for therapeutic targeting.
    Yee NS
    Cancer Biol Ther; 2011 Jun; 11(11):969-73. PubMed ID: 21610317
    [No Abstract]   [Full Text] [Related]  

  • 2. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.
    Feldmann G; Karikari C; dal Molin M; Duringer S; Volkmann P; Bartsch DK; Bisht S; Koorstra JB; Brossart P; Maitra A; Fendrich V
    Cancer Biol Ther; 2011 Jun; 11(11):959-68. PubMed ID: 21455033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
    Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic Cancer: A Review.
    Yabar CS; Winter JM
    Gastroenterol Clin North Am; 2016 Sep; 45(3):429-45. PubMed ID: 27546841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    Singh HM; Bailey P; Hübschmann D; Berger AK; Neoptolemos JP; Jäger D; Siveke J; Springfeld C
    Genes Chromosomes Cancer; 2021 May; 60(5):373-384. PubMed ID: 33341987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition.
    Gallmeier E; Kern SE
    Cancer Biol Ther; 2005 Jul; 4(7):703-6. PubMed ID: 16082177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.
    Rowley M; Ohashi A; Mondal G; Mills L; Yang L; Zhang L; Sundsbak R; Shapiro V; Muders MH; Smyrk T; Couch FJ
    Gastroenterology; 2011 Apr; 140(4):1303-1313.e1-3. PubMed ID: 21199651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.
    Skoulidis F; Cassidy LD; Pisupati V; Jonasson JG; Bjarnason H; Eyfjord JE; Karreth FA; Lim M; Barber LM; Clatworthy SA; Davies SE; Olive KP; Tuveson DA; Venkitaraman AR
    Cancer Cell; 2010 Nov; 18(5):499-509. PubMed ID: 21056012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
    Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
    Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
    Chapin WJ; Reiss KA
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.
    Candido S; Abrams SL; Steelman LS; Lertpiriyapong K; Martelli AM; Cocco L; Ratti S; Follo MY; Murata RM; Rosalen PL; Bueno-Silva B; de Alencar SM; Lombardi P; Mao W; Montalto G; Cervello M; Rakus D; Gizak A; Lin HL; Libra M; Akula SM; McCubrey JA
    Adv Biol Regul; 2019 May; 72():22-40. PubMed ID: 30898612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
    Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.
    Hattori H; Skoulidis F; Russell P; Venkitaraman AR
    Mol Cancer Ther; 2011 Apr; 10(4):670-8. PubMed ID: 21289082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.
    Zhao XS; Zhou J; Dong L; Zhang H; Ye YJ
    Chin Med J (Engl); 2019 Dec; 132(24):3012-3014. PubMed ID: 31764178
    [No Abstract]   [Full Text] [Related]  

  • 15. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
    de Mestier L; Danset JB; Neuzillet C; Rebours V; Cros J; Soufir N; Hammel P
    Endocr Relat Cancer; 2016 Oct; 23(10):T57-67. PubMed ID: 27511924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.
    Ottenhof NA; de Wilde RF; Morsink FH; de Leng WW; Ausems MG; Morreau H; van Hillegersberg R; Offerhaus GJ; Milne AN
    Hum Pathol; 2012 Mar; 43(3):457-61. PubMed ID: 21992816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model.
    Alves F; Borchers U; Padge B; Augustin H; Nebendahl K; Klöppel G; Tietze LF
    Cancer Lett; 2001 Apr; 165(2):161-70. PubMed ID: 11275365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New biomarkers and targets in pancreatic cancer and their application to treatment.
    Costello E; Greenhalf W; Neoptolemos JP
    Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):435-44. PubMed ID: 22733351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
    Saif MW
    JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
    [No Abstract]   [Full Text] [Related]  

  • 20. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
    Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.